|
1.
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
|
|
2.
|
Yang L: Incidence and mortality of gastric
cancer in China. World J Gastroenterol. 12:17–20. 2006.
|
|
3.
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
4.
|
GASTRIC (Global Advanced/Adjuvant Stomach
Tumor Research Collaboration) Group; Paoletti X, Oba K, Burzykowski
T, et al: Benefit of adjuvant chemotherapy for resectable gastric
cancer: a meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Zou Z, Anisowicz A, Hendrix MJ, et al:
Maspin, a serpin with tumor-suppressing activity in human mammary
epithelial cells. Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ogasawara S, Maesawa C, Yamamoto M, et al:
Disruption of cell-type-specific methylation at the Maspin gene
promoter is frequently involved in undifferentiated thyroid
cancers. Oncogene. 23:1117–1124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Umekita Y, Ohi Y, Sagara Y, et al:
Expression of maspin predicts poor prognosis in breast-cancer
patients. Int J Cancer. 100:452–455. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Ohike N, Maass N, Mundhenke C, et al:
Clinicopathological significance and molecular regulation of maspin
expression in ductal adenocarcinoma of the pancreas. Cancer Lett.
199:193–200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Sood AK, Fletcher MS, Gruman LM, et al:
The paradoxical expression of maspin in ovarian carcinoma. Clin
Cancer Res. 8:2924–2932. 2002.PubMed/NCBI
|
|
10.
|
Kim SM, Cho SJ, Jang WY, et al: Expression
of maspin is associated with the intestinal type of gastric
adenocarcinoma. Cancer Res Treat. 37:228–232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Song SY, Son HJ, Kim MH, et al: Prognostic
significance of maspin expression in human gastric adenocarcinoma.
Hepatogastroenterology. 54:973–976. 2007.PubMed/NCBI
|
|
12.
|
Harvey JM, Clark GM, Osborne CK, et al:
Estrogen receptor status by immunohistochemistry is superior to the
ligand-binding assay for predicting response to adjuvant endocrine
therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.
|
|
13.
|
Boku N: Perspectives for personalization
in chemotherapy of advanced gastric cancer. Discov Med. 9:84–89.
2010.PubMed/NCBI
|
|
14.
|
Wagner AD, Grothe W, Haerting J, et al:
Chemotherapy in advanced gastric cancer: a systematic review and
meta-analysis based on aggregate data. J Clin Oncol. 24:2903–2909.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Won HJ, Ha TK, Kwon SJ, et al:
Differential effects of 5-fluorouracil on glucose transport and
expressions of glucose transporter proteins in gastric cancer
cells. Anticancer Drugs. 21:270–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jakobsen A, Nielsen JN, Gyldenkerne N, et
al: Thymidylate synthase and methylenetetrahydrofolate reductase
gene polymorphism in normal tissue as predictors of fluorouracil
sensitivity. J Clin Oncol. 23:1365–1369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ajani JA: Evolving chemotherapy for
advanced gastric cancer. Oncologist. 10(Suppl 3): 49–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Park DJ and Lenz HJ: Determinants of
chemosensitivity in gastric cancer. Curr Opin Pharmacol. 6:337–344.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kubota T and Weisenthal L: Chemotherapy
sensitivity and resistance testing: to be ‘standard’ or to be
individualized, that is the question. Gastric Cancer. 9:82–87.
2006.
|
|
20.
|
Dietmaier W, Bettstetter M, Wild PJ, et
al: Nuclear Maspin expression is associated with response to
adjuvant 5-fluorouracil based chemotherapy in patients with stage
III colon cancer. Int J Cancer. 118:2247–2254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zheng Z, Li J, He X, et al: Involvement of
RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil.
Hepatogastroenterology. 57:1106–1112. 2010.PubMed/NCBI
|
|
22.
|
Sheng S, Truong B, Fredrickson D, et al:
Tissue-type plasminogen activator is a target of the tumor
suppressor gene maspin. Proc Natl Acad Sci USA. 95:499–504. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Dokras A, Gardner LM, Kirschmann DA, et
al: The tumour suppressor gene maspin is differentially regulated
in cytotrophoblasts during human placental development. Placenta.
23:274–280. 2002. View Article : Google Scholar
|
|
24.
|
Shi HY, Zhang W, Liang R, et al: Modeling
human breast cancer metastasis in mice: maspin as a paradigm.
Histol Histopathol. 18:201–206. 2003.PubMed/NCBI
|
|
25.
|
Zhang M, Volpert O, Shi YH, et al: Maspin
is an angiogenesis inhibitor. Nat Med. 6:196–199. 2000. View Article : Google Scholar
|
|
26.
|
Mohsin SK, Zhang M, Clark GM, et al:
Maspin expression in invasive breast cancer: association with other
prognostic factors. J Pathol. 199:432–435. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Marioni G, Blandamura S, Giacomelli L, et
al: Nuclear expression of maspin is associated with a lower
recurrence rate and a longer disease-free interval after surgery
for squamous cell carcinoma of the larynx. Histopathology.
46:576–582. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Lee DY, Park CS, Kim HS, et al: Maspin and
p53 protein expression in gastric adenocarcinoma and its clinical
applications. Appl Immunohistochem Mol Morphol. 16:13–18.
2008.PubMed/NCBI
|
|
29.
|
Ben Shachar B, Feldstein O, Hacohen D, et
al: The tumor suppressor maspin mediates E2F1-induced sensitivity
of cancer cells to chemotherapy. Mol Cancer Res. 8:363–372.
2010.PubMed/NCBI
|
